Bevacizumab in the treatment of NSCLC: patient selection and perspectives

Código QR

Bevacizumab in the treatment of NSCLC: patient selection and perspectives

Alessia E Russo,1 Domenico Priolo,1 Giovanna Antonelli,1 Massimo Libra,2 James A McCubrey,3 Francesco Ferraù1 1Medical Oncology Department, San Vincenzo Hospital, Taormina (Messina), Italy; 2Laboratory of Translational Oncology & Functional Genomics, Department of Biomedical and B...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Russo AE, Priolo D, Antonelli G, Libra M, Mccubrey JA, Ferraù F
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	bevacizumab non-squamous NSCLC eligibility safety subpopulations Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/2a66d4dedbe34532a248193ff955aadc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study
por: Rui Wan, et al.
Publicado: (2021)

Efficacy and Safety of Different Doses of Bevacizumab Combined With Pemetrexed and Platinum in First-Line Treatment of Advanced NSCLC: A Retrospective-Real World Study
por: Chun-Hua Zhou, et al.
Publicado: (2021)

65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer
por: Schuette W, et al.
Publicado: (2017)

Câncer colorretal: uma revisão da abordagem terapêutica com bevacizumabe
por: Lenita Maria Tonon, et al.
Publicado: (2007)

Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)
por: Giustini N, et al.
Publicado: (2021)

Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
por: Anwen Xiong, et al.
Publicado: (2021)

New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer
por: Niki M, et al.
Publicado: (2017)

nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy
por: Thomas M, et al.
Publicado: (2017)

Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy
por: Masatoshi Kudo
Publicado: (2021)

A Pilot Study to Evaluate Early Predictive Value of Thorax Perfusion-CT in Advanced NSCLC
por: Francisco Aya, et al.
Publicado: (2021)

Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
por: Zhang SS, et al.
Publicado: (2021)

A Comparison of Bevacizumab Plus TAS-102 and TAS-102 Monotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
por: Xiaochen Chen, et al.
Publicado: (2021)

Case Report: Sequential Combination Targeted Therapy With Type I and II MET Inhibitors in a Metastatic EGFR-Mutated, MET-Amplified NSCLC Patient With Acquired MET Y1230H Mutation
por: Boning Cai, et al.
Publicado: (2021)

Premalignant Changes in the Bronchial Epithelium Are Prognostic Factors of Distant Metastasis in Non-Small Cell Lung Cancer Patients
por: Olga V. Pankova, et al.
Publicado: (2021)

Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study
por: Jean-Louis Pujol, MD, PhD, et al.
Publicado: (2021)

Case Report: Dacomitinib Overcomes Osimertinib Resistance in NSCLC Patient Harboring L718Q Mutation: A Case Report
por: Qian Shen, et al.
Publicado: (2021)

Preliminary Efficacy and Safety of Camrelizumab in Combination With XELOX Plus Bevacizumab or Regorafenib in Patients With Metastatic Colorectal Cancer: A Retrospective Study
por: Hong Zhou, et al.
Publicado: (2021)

Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases
por: Zhu VW, et al.
Publicado: (2020)

Intracranial response to a combination of bevacizumab and epirubicin for an adenoid cystic carcinoma of the external auditory canal: A case report and review of the literature
por: Nuria Mederos, et al.
Publicado: (2021)

HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
por: Gan J, et al.
Publicado: (2021)

Practical management of NSCLC patients with long-term bevacizumab treatment: a report of four cases
por: Herder GJM, et al.
Publicado: (2013)

Bevacizumab treatment in the elderly patient with metastatic colorectal cancer
por: Di Bartolomeo M, et al.
Publicado: (2015)

Phase I Dose-Escalation Trial of an Innovative Chemotherapy Regimen Combining a Fractionated Dose of Irinotecan Plus Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Folinic Acid (bFOLFIRINOX-3) in Chemorefractory Metastatic Colorectal Cancer
por: Hélène Bellio, et al.
Publicado: (2021)

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
por: Barrows SM, et al.
Publicado: (2019)

circ_0005962 functions as an oncogene to aggravate NSCLC progression
por: Zhang Zhihong, et al.
Publicado: (2021)

Tratamiento de la retinopatía del prematuro con bevacizumab intravítreo
por: BANCALARI M,ALDO, et al.
Publicado: (2013)

Effects of Intravitreal Bevacizumab Therapy in Patients with Proliferative Diabetic Retinopathy
por: Ribeiro de Carvalho G, et al.
Publicado: (2020)

The First WHO International Standard for Harmonizing the Biological Activity of Bevacizumab
por: Haiyan Jia, et al.
Publicado: (2021)

Short-Term Changes in Intraocular Pressure After Intravitreal Injection of Bevacizumab for the Treatment of Retinopathy of Prematurity
por: Obata S, et al.
Publicado: (2019)

Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival
por: Fiamma Berner, et al.
Publicado: (2021)

Bevacizumab-Induced Geographic Tongue
por: Marta Martinez-Garcia, et al.
Publicado: (2021)

Glaucoma drainage device implantation with adjunctive intravitreal bevacizumab in neovascular glaucoma: 3-year experience
por: Noor NA, et al.
Publicado: (2017)

Cancer cell-derived exosomal circUSP7 induces CD8+ T cell dysfunction and anti-PD1 resistance by regulating the miR-934/SHP2 axis in NSCLC
por: Shi-Wei Chen, et al.
Publicado: (2021)

MET overexpression and gene amplification in NSCLC: a clinical perspective
por: Landi L, et al.
Publicado: (2013)

The effect of local immunity on gastric cancer prognosis
por: Gulnoz G. Khakimova, et al.
Publicado: (2020)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
por: Pessoa B, et al.
Publicado: (2021)

Role of afatinib in the treatment of advanced lung squamous cell carcinoma
por: Vavalà T
Publicado: (2017)

Incidence of ROS1-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients
por: Mehta A, et al.
Publicado: (2020)

Anti-Angiogenic Activity Of Bevacizumab-Bearing Dexamethasone-Loaded PLGA Nanoparticles For Potential Intravitreal Applications
por: Liu J, et al.
Publicado: (2019)

Polo-like kinase 1 inhibition in NSCLC: mechanism of action and emerging predictive biomarkers
por: Stratmann JA, et al.
Publicado: (2019)